Pershing Square USA, Ltd. Releases 2026 Semi-Annual Report

Pershing Square USA, Ltd. Releases 2026 Semi-Annual Report

NEW YORK–(BUSINESS WIRE)–
Pershing Square USA, Ltd. (NYSE:PSUS) today released its Semi-Annual Report which includes the Investment Manager’s quarterly portfolio review. The report is now available on the PSUS website, https://pershingsquareusa.com/materials/.

About Pershing Square USA, Ltd.

Pershing Square USA, Ltd. (NYSE:PSUS) is a closed-end management investment company managed by Pershing Square Capital Management, L.P.

Category: (PSUS:FinancialReporting)

Fran McGill

[email protected]

212-909-2455

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Insulet Corporation Investors With Significant Losses Must Act By August 31, 2026

NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) — Kirby McInerney LLP reminds Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) investors of the August 31, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Investors are encouraged to contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of February 21, 2025 through May 26, 2026, inclusive (“the Class Period”). The lawsuit alleges throughout the Class Period, Insulet made public statements that were misleading for failure to disclose that: (i) Insulet’s manufacturing controls and procedures were defective and (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury.

On March 12, 2026, Insulet disclosed that it had “initiated a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods after identifying a manufacturing issue through its ongoing product monitoring.” On this news, the price of Insulet shares declined by $16.23 per share, or approximately 7%, from $236.07 per share on March 12, 2026 to close at $219.84 on March 13, 2026.

Then, on May 26, 2026, Insulet disclosed the “initiation” of another “voluntary Medical Device Correction,” this time “for specific lots of Omnipod 5, Omnipod Dash, and Omnipod Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery.” On this news, the price of Insulet shares declined by $7.79 per share, or approximately 5%, from $153.80 per share on May 26, 2026 to close at $146.01 on May 27, 2026.

[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]

What Should I Do?

If you purchased or otherwise acquired Insulet securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

What is the Lead Plaintiff Deadline?

Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. Learn more about the lead plaintiff process and eligibility requirements here.

[WHAT IS A SECURITIES CLASS ACTION?]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Kirby McInerney LLP
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
[email protected]



Global Water Resources Reports Second Quarter 2026 Results

PHOENIX, Aug. 12, 2026 (GLOBE NEWSWIRE) — Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, reported results for the three and six months ended June 30, 2026. Unless otherwise noted, all comparisons are to the corresponding period in the prior year. The company will hold a conference call at 1:00 p.m. Eastern time tomorrow to discuss the results (see dial-in information below).

Q2 2026 Financial Highlights

  • Total revenue increased $3.5 million or 24.8% year-over-year (YoY) to $17.8 million. The increase was primarily due to the recognition of $2.1 million in unregulated revenue related to infrastructure coordination and financing agreements (ICFA), the acquisition of seven water systems from Tucson Water in July 2025, organic connection growth, increased consumption and higher rates.
  • Regulated revenue increased $1.4 million or 9.9% to $15.7 million YoY, primarily due to the acquisition of seven water systems from Tucson Water in July 2025, organic connection growth, increased consumption and higher rates.
  • Net income increased $1.1 million to $2.7 million or $0.10 per diluted share, as compared to net income of $1.6 million or $0.06 per diluted share in the second quarter of 2025. The increase primarily reflects the company’s ICFA revenue recognized, the acquisition of seven water systems from Tucson Water in July 2025, and organic growth, partially offset by increased depreciation expense and net interest expense resulting from the company’s 2025 rate base investments.
  • Adjusted EBITDA, a non-GAAP measure, increased $1.0 million YoY to $7.9 million in the second quarter of 2026 (see definition of adjusted EBITDA, and its reconciliation to GAAP, below).
  • Declared three monthly cash dividends of $0.02533 per common share or $0.30396 per common share on an annualized basis.

Q2 2026 Operational Highlights

  • Total active service connections at June 30, 2026 increased 5.8% YoY to 69,429.
  • Annualized active service connection growth rate, excluding the acquisition of seven water systems from Tucson Water, was 2.6%.
  • Water consumption increased 6.1% YoY to 1.2 billion gallons.
  • Invested $6.6 million in Q2 2026 in infrastructure projects to support existing utilities and continued growth.
  • On April 28, 2026, the company filed a settlement agreement with the Arizona Corporation Commission (ACC) detailing the terms upon which the parties have agreed, subject to ACC approval, to bifurcate and settle the rate cases for Global Water – Santa Cruz Water Company, Inc. (GW-Santa Cruz) and Global Water – Palo Verde Utilities Company, Inc. (GW-Palo Verde). Among other things, the parties have agreed to:
    • an increase in GW-Santa Cruz’s annual revenue requirement of approximately $2.3 million,
    • a requested effective date of the new rates for GW-Santa Cruz of November 1, 2026; and,
    • the withdrawal of the GW-Palo Verde rate case, to be refiled in 2027 using a 2026 test year without seeking formula rates.
  • In consideration of the settlement agreement, GW-Palo Verde committed to seek an increase to the amount of the temporary bill credit for its customers of approximately $0.4 million annually until resolution of the next GW-Palo Verde rate case. The increase to the temporary bill credit is anticipated to coincide with the new rates described above for GW-Santa Cruz going into effect.
  • Filed Designation of Assured Water Supply applications to expand assured water supply and support long-term growth in GW-Santa Cruz and GW-Ocotillo service areas.
  • Secured an extension of the company’s $20 million revolving line of credit to May 18, 2028.

Subsequent Events

  • On July 9, 2026, GW-Palo Verde filed a motion to withdraw its rate application in accordance with the settlement agreement. The motion was granted on July 29, 2026.
  • On August 3, 2026, hearings concluded on the GW-Santa Cruz rate case, and the case, including the settlement agreement, is under advisement with the ALJ.

Management Commentary

“In Q2, we generated strong year-over-year growth,” commented Global Water Resources President and CEO, Ron Fleming. “The 9.9% increase in regulated revenue was primarily driven by the Tucson acquisition, the 2.7% organic active connections growth and higher water consumption in a rapidly expanding metropolitan region.

“Revenue also benefited from higher rates at GW-Farmers following a successful general rate case in Southern Arizona. We expect the additional revenue to help fund current and future customer needs, including high-quality water infrastructure and improved service for the communities we serve.

“As previously reported, we completed several significant 2025 capital investments to support growth and enhance long-term system reliability. These included recommissioning our Southwest Plant water reclamation facility, capital improvements to stay ahead of community growth, and the acquisition of seven water systems from the City of Tucson. While these projects increased depreciation as assets entered service, they expanded and strengthened our infrastructure, improved customer service capacity, and support long-term shareholder value.

“Importantly, second quarter general and administrative expense was slightly lower year-over-year, reflecting continued cost discipline. Depreciation, amortization and accretion increased primarily from assets placed in service following our 2025 capital improvement plan and related investments. Although these non-cash expenses can affect near-term net income and earnings per share, they reflect capital deployed into infrastructure that supports growth, service quality, and customer and community needs. Appropriate rate relief remains important to recovering these investments and addressing inflationary pressures across our utilities.

“In May, we filed testimony supporting a settlement to bifurcate rate cases for GW-Santa Cruz and GW-Palo Verde, our largest water and wastewater utilities. The regulatory hearing has concluded, our legal brief is complete, and we are awaiting the administrative law judge’s recommended opinion and order for commissioner review and vote. As a reminder, the settlement proposes a net $1.9 million rate increase. A final decision is expected in the fourth quarter with new rates for GW-Santa Cruz requested to be effective November 1, 2026.

“Regarding GW-Palo Verde, we filed a motion to withdraw our rate review application. The motion was granted, and we intend to refile in 2027 using a 2026 test year. A growing rate base from prudent infrastructure investments is expected to support future rate case filings and appropriate rate increases, helping drive revenue growth and fund current and future customer needs.

“During the quarter, we continued to invest prudently in core service areas where we can deploy our Total Water Management model, including required maintenance capital and new water and wastewater treatment and delivery facilities. For example, our Hassayampa utility commissioned a new 60,000-gallon-per-day water reclamation facility serving a planning and service area in western Maricopa County, Arizona, within Phoenix’s growth corridors.

“Looking ahead, we expect continued organic connection growth driven by Arizona’s strong economic outlook. On July 16, 2026, TSMC announced an additional $100 billion investment for U.S. semiconductor manufacturing, bringing TSMC’s total planned Arizona investment to a record $265 billion. The funding will support four additional advanced chip manufacturing and packaging facilities in Arizona, totaling 12 U.S. sites, and is expected to create tens of thousands of jobs across the state, including Metro Phoenix and Tucson.

“Beyond manufacturing, we believe Arizona’s broader economy is positioned to accelerate in 2026, supported by population and job growth. Arizona’s Office of Economic Opportunity projects employment will increase by 454,000 jobs through 2034, an annual growth rate of 1.2%, or four times the national average of 0.3%.

“We are also pleased that the State Route 347 Improvement Project began in June. The project will widen the 14-mile corridor by adding one lane in each direction and upgrading bridges and intersections to ease congestion. We expect it to support residential and commercial development and increase demand for water, wastewater and recycled water services in the City of Maricopa and western Pinal County.

“As part of our long-term regulatory planning, we expect to pursue future rate review filings over the next few years. As previously mentioned, we intend to start with GW-Palo Verde, followed by a rate review for, and consolidation of, our Pima County utilities, including GW-Saguaro, GW-Ocotillo, and GW-Farmers. These cases are expected to use a 2026 test year, which we intend to file in the first half of 2027. Finally, we are planning a GW-Santa Cruz rate review filing in the first half of 2028 using a 2027 test year. For the remainder of 2026 and beyond, we plan to continue to make prudent infrastructure investments across all our utilities as we build a strong regulatory record to support appropriate recovery of these investments.”

Financial Summary for the
Three Months Ended June 30, 2026
and
2025

Revenue

  Three Months Ended Favorable (Unfavorable)
  June 30, 2026 vs. 2025
(in thousands)   2026   2025   %
Water service $ 8,404 $ 7,368 $ 1,036 14.1 %
Wastewater and recycled water service   7,252   6,873   379 5.5 %
Total regulated revenue   15,656   14,241   1,415 9.9 %
Unregulated revenue   2,111     2,111 N/M
Total revenue $ 17,767 $ 14,241 $ 3,526 24.8 %
                 

N/M denotes a change not considered meaningful due to immaterial prior year value

The increase in regulated revenue for the three months ended June 30, 2026 as compared to the three months ended June 30, 2025 was primarily attributable to:

  • The acquisition of the seven water systems from the City of Tucson in July 2025.
  • Organic growth in active water and wastewater connections.
  • Increased water consumption, predominantly driven by growth in active connections and higher usage largely as a result of higher temperatures and drier weather during the current year period.
  • Higher rates for GW-Farmers resulting from the GW-Farmers general rate case, effective November 1, 2025 and May 1, 2026.

The increase in unregulated revenue for the three months ended June 30, 2026 as compared to the three months ended June 30, 2025 was related to ICFA revenue recorded in connection with the commissioning of a new wastewater reclamation facility in GW-Hassayampa’s service territory in June 2026.

Operating Expenses

  Three Months Ended Favorable (Unfavorable)
  June 30, 2026 vs. 2025
(in thousands)   2026   2025 $ %
Personnel costs – operations and maintenance $ 1,538 $ 1,356 $ (182 ) (13.4)%
Utilities, chemicals and repairs   1,388   1,183   (205 ) (17.3)%
Other operations and maintenance expenses   1,629   1,378   (251 ) (18.2)%
Total operations and maintenance expense   4,555   3,917   (638 ) (16.3)%
Personnel costs – general and administrative   2,054   2,236   182   8.1 %
Professional fees   355   441   86   19.5 %
Other general and administrative expenses   1,896   1,710   (186 ) (10.9)%
Total general and administrative expense   4,305   4,387   82   1.9 %
Depreciation, amortization and accretion   4,401   3,317   (1,084 ) (32.7)%
Total operating expenses $ 13,261 $ 11,621 $ (1,640 ) (14.1)%
                 

Operations and Maintenance

  • Higher personnel costs were primarily attributable to rising medical costs.
  • Higher utilities, chemicals and repairs were primarily the result of increased purchased power driven by increased consumption and additional processing equipment in operation as a result of our 2025 capital improvement plan. Increased consumption also resulted in increased expenditures for chemicals and supplies.
  • The increase in other operations and maintenance expenses was primarily driven by a $0.1 million loss on the disposal of utility plant and expenses related to wastewater disposal prior to the start-up of the GW-Hassayampa wastewater reclamation facility in June 2026 and $0.1 million in new operating costs for the seven water systems acquired from the City of Tucson in July 2025.

General and Administrative

  • Lower personnel costs were primarily driven by decreased hiring and moving expenses and lower salaries and wages, partially offset by increased medical costs.
  • The decrease in professional fees was largely attributable to higher legal fees in the prior year period associated with the Nikola bankruptcy and the acquisition of the seven water systems from the City of Tucson in July 2025.
  • The increase in other general and administrative expenses was primarily attributable to:
    • Increased rent expense related to the renewal of our corporate office lease in August 2025.
    • Higher general liability insurance costs.

Depreciation, Amortization and Accretion

The increase for the three months ended June 30, 2026 as compared to the three months ended June 30, 2025 was substantially attributable to an 18.8% increase in depreciable fixed assets as a result of our 2025 capital improvement plan, which resulted in a significant number of assets placed in service in the fourth quarter of 2025.

Total Other Expense

The increase of $0.4 million in other expense to $0.8 million for the three months ended June 30, 2026 as compared to $0.4 million for the three months ended June 30, 2025 was substantially attributable to:

  • An increase in interest expense of $0.2 million primarily due to a term loan entered into in December 2025 to support our 2025 capital improvement plan and increased borrowings under the Revolver in the current year period.
  • A decrease in interest income of $0.2 million as a result of carrying lower average cash balances.

Net Income

Net income increased $1.1 million or 70.4% to $2.7 million or $0.10 per diluted share in the second quarter of 2026, compared to net income of $1.6 million or $0.06 per diluted share in the second quarter of 2025. The increase primarily reflects the company’s ICFA revenue recognized, the acquisition of seven water systems from Tucson Water in July 2025, and organic growth, partially offset by increased depreciation expense and net interest expense, resulting from the company’s 2025 rate base investments.

Adjusted EBITDA

Adjusted EBITDA increased $1.0 million or 14.6% to $7.9 million in the second quarter of 2026, compared to $6.9 million in the same period in 2025. The increase was primarily the result of regulated revenue growth.

Adjusted Net Income

Adjusted net income, a non-GAAP measure, was $1.3 million in the second quarter of 2026, compared to $1.6 million in the same period in 2025. The decrease is primarily the result of higher depreciation, amortization and accretion expense, partially offset by an increase in regulated revenue.

Financial Summary for the Six Months Ended June 30, 2026 and 2025

Revenue

  Six Months Ended Favorable (Unfavorable)
  June 30, 2026 vs. 2025
(in thousands)   2026   2025   %
Water service $ 15,010 $ 13,348 $ 1,662 12.4 %
Wastewater and recycled water service   13,932   13,350   582 4.4 %
Total regulated revenue   28,942   26,698   2,244 8.4 %
Unregulated revenue   2,111     2,111 N/M
Total revenue $ 31,053 $ 26,698 $ 4,355 16.3 %
                 

N/M denotes a change not considered meaningful due to immaterial prior year value

The increase in regulated revenue for the six months ended June 30, 2026 as compared to the six months ended June 30, 2025 was primarily attributable to:

  • The acquisition of the seven water systems from the City of Tucson in July 2025.
  • Organic growth in active water and wastewater connections.
  • Increased water consumption, predominantly driven by growth in active connections and higher usage largely as a result of higher temperatures and drier weather during the current year period.
  • Higher rates for GW-Farmers resulting from the GW-Farmers general rate case, effective November 1, 2025 and May 1, 2026.

The increase in unregulated revenue for the six months ended June 30, 2026 as compared to the six months ended June 30, 2025 was related to ICFA revenue recorded in connection with the commissioning of a new wastewater reclamation facility in GW-Hassayampa’s service territory in June 2026.

Operating Expenses

  Six Months Ended Favorable (Unfavorable)
  June 30, 2026 vs. 2025
(in thousands)   2026   2025 $ %
Personnel costs – operations and maintenance $ 3,021 $ 2,696 $ (325 ) (12.1)%
Utilities, chemicals and repairs   2,560   2,215   (345 ) (15.6)%
Other operations and maintenance expenses   3,158   2,693   (465 ) (17.3)%
Total operations and maintenance expense   8,739   7,604   (1,135 ) (14.9)%
Personnel costs – general and administrative   4,411   4,431   20   0.5 %
Professional fees   744   908   164   18.1 %
Other general and administrative expenses   3,602   3,235   (367 ) (11.3)%
Total general and administrative expense   8,757   8,574   (183 ) (2.1)%
Depreciation, amortization and accretion   8,662   6,645   (2,017 ) (30.4)%
Total operating expenses $ 26,158 $ 22,823 $ (3,335 ) (14.6)%
                 

Operations and Maintenance

  • Higher personnel costs were primarily attributable to rising medical costs.
  • Higher utilities, chemicals and repairs were primarily the result of increased purchased power driven by increased consumption and additional processing equipment in operation as a result of our 2025 capital improvement plan. Increased consumption also resulted in increased expenditures for chemicals and supplies.
  • The increase in other operations and maintenance expenses was primarily driven by a $0.1 million loss on the disposal of utility plant and expenses related to wastewater disposal prior to the start-up of the GW-Hassayampa wastewater reclamation facility in June 2026 and $0.1 million in new operating costs for the seven water system acquired from the City of Tucson in July 2025.

General and Administrative

  • Lower professional fees were substantially the result of higher legal fees in the prior year period associated with the Nikola bankruptcy and the acquisition of the seven water systems from the City of Tucson.
  • The increase in other general and administrative expenses was primarily attributable to:
    • Increased contract service costs primarily associated with increased IT expenses.
    • Increased rent expense related to the renewal of our corporate office lease in August 2025.
    • Higher general liability insurance costs.

Depreciation, Amortization and Accretion

The increase for the six months ended June 30, 2026 as compared to the six months ended June 30, 2025 was substantially attributable to an 18.8% increase in depreciable fixed assets as a result of our 2025 capital improvement plan, which resulted in a significant number of assets placed in service in the fourth quarter of 2025. In addition, amortization of intangible assets increased in the first quarter of 2026 in connection with ICFA payments received.

Total Other Expense

The increase of $0.7 million in total other expense to $1.6 million for the six months ended June 30, 2026 as compared to $0.9 million for the six months ended June 30, 2025 was substantially attributable to:

  • An increase in interest expense of $0.4 million primarily due to a term loan entered into in December 2025 to support our 2025 capital improvement plan and increased borrowings under the Revolver in the current year period.
  • A decrease in interest income of $0.2 million as a result of carrying lower average cash balances.
  • A decrease in income associated with Buckeye growth premiums of $0.1 million that resulted from fewer new meter connections in the area.

Net Income

Net income increased $0.2 million or 8.1% to $2.4 million or $0.08 per diluted share in the six months ended June 30, 2026, compared to net income of $2.2 million or $0.08 per diluted share in the six months ended June 30, 2025. The primary drivers include ICFA revenue recognition, the acquisition of seven water systems from Tucson Water in July 2025, and organic growth partially offset by increased depreciation expense and net interest expense as a result of the company’s 2025 capital improvement plan.

Adjusted EBITDA

Adjusted EBITDA, a non-GAAP measure, increased $0.9 million or 7.6% to $13.5 million for the six months ended June 30, 2026, compared to $12.6 million in the same period in 2025. The increase is primarily attributable to higher regulated revenue, partially offset by increases in operations and maintenance expenses.

Adjusted Net Income

Adjusted net income, a non-GAAP measure, was $0.9 million for the six months ended June 30, 2026, compared to $2.2 million in the same period in 2025. The decrease is primarily the result of higher depreciation, amortization and accretion expense, partially offset by an increase in regulated revenue.

Dividend Policy

The company recently declared a monthly cash dividend of $0.02533 per common share (or $0.30396 per share on an annualized basis), payable on August 31, 2026, to holders of record at the close of business on August 17, 2026.

Business Strategy

Global Water’s near-term growth strategy involves increasing service connections, improving operating efficiencies, and increasing utility rates as approved by the ACC. The company plans to continue aggregating water and wastewater utilities through strategic acquisitions and entity consolidation, which is expected to enable the company and its customers to realize the benefits of consolidation, regionalization, and environmental stewardship.

Connection Rates

As of June 30, 2026, active service connections increased by 3,790 or 5.8% to 69,429 compared to 65,639 at June 30, 2025. The increase in active service connections was primarily due to new connections associated with the seven acquired water systems from Tucson Water and organic growth in the company’s service areas.

Arizona’s Growth Corridor: Positive Population and Economic Trends

The company continues to experience organic growth exhibited through its year-over-year organic increase in active connections (i.e., exclusive of acquisition related growth) of 2.7% as of June 30, 2026. According to the 2025 U.S. Census estimates, the Phoenix metropolitan statistical area (MSA) is the 10th largest MSA in the U.S. and had an estimated population of 5.2 million, an increase of 7.9% over the 4.8 million people reported in the 2020 Census. Growth in the Phoenix MSA continues as a result of its excellent weather, large and growing universities, a diverse employment base, and low taxes. The Arizona Office of Economic Opportunity predicts that the Phoenix metropolitan area will have a population of 5.7 million people by 2030 and 6.3 million by 2040.

The company’s organic growth continues to be primarily influenced by the comparatively lower cost of housing in the City of Maricopa relative to other areas within the Phoenix MSA. As of June 2026, the median home sales price in the City of Maricopa was 25% lower than in the City of Phoenix. In addition, construction on the State Route 347 Improvement Project began in June 2026, with completion scheduled for 2029. The project represents a transformative investment in regional infrastructure that the company believes will enhance safety, improve mobility and support the continued growth of the City of Maricopa and surrounding areas.

The company continues to monitor potential effects on its operations due to changes in the macroeconomic environment, such as the impacts of tariffs on its operational costs and construction work in progress, as well as new home construction in the company’s service areas. The company continues to expect a positive long-term outlook based on forecasted performance of job and population growth, as well as indicators of stabilizing construction in the single-family housing market in the Phoenix MSA.

While new permit activity has slowed, growth in the Phoenix MSA, particularly in the City of Maricopa, is reflected in the company’s 2.7% year-over-year organic increase in active connections. Management believes, despite fluctuations in permit projections, the company remains well-positioned to benefit from the anticipated long-term growth of the Phoenix MSA.

Conference Call

Global Water Resources will hold a conference call tomorrow to discuss its second quarter of 2026 results, including a question-and-answer period.

Date: Thursday, August 13, 2026
Time: 1:00 p.m. Eastern time (10:00 a.m. local time)
Toll-free dial-in number: 1-833-816-1435
International dial-in number: 1-412-317-0527
Conference ID: 10208204
Webcast (live and replay): here

The conference call webcast is also available via a link in the Investors section of the company’s website at www.gwresources.com.

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you require any assistance connecting to the call, please contact Encore at 1-949-432-7450.

A replay of the call will be available after 4:00 p.m. Eastern time on the same day through August 27, 2026.

Toll-free replay number: 1-844-512-2921
International replay number: 1-412-317-6671
Replay ID: 10208204

About Global Water Resources

Global Water Resources, Inc. is a leading water resource management company that owns and operates 39 systems which provide water, wastewater, and recycled water service. The company’s service areas are located primarily in growth corridors around metropolitan Phoenix and Tucson. Global Water recycles over 1 billion gallons of water annually with 19.9 billion gallons recycled since 2004.

The company has been recognized for its highly effective implementation of Total Water Management (TWM). TWM is an integrated approach to managing the entire water cycle that involves owning and operating water, wastewater and recycled water utilities within the same geographic area in order to maximize the beneficial use of recycled water. It enables smart water management programs such as remote metering infrastructure and other advanced technologies, rate designs, and incentives that result in real conservation. TWM helps protect water supplies in water-scarce areas experiencing population growth.

Global Water has received numerous industry awards, including national recognition as a ‘Utility of the Future Today’ for its superior water reuse practices by a national consortium of water and conservation organizations led by the Water Environment Federation (WEF). The company also received Cityworks’ Excellence in Departmental Practice Award for demonstrating leadership and creativity in applying public asset management strategies to daily operations and long-term planning.

To learn more, visit www.gwresources.com.

Use of Non-GAAP Measures

This press release contains certain financial measures that are not recognized measures under accounting principles generally accepted in the United States of America (“GAAP”), including EBITDA, adjusted EBITDA, adjusted net income, and adjusted diluted earnings per common share. EBITDA is defined for the purposes of this press release as net income before interest, income taxes, depreciation, amortization and accretion. Adjusted EBITDA is defined as EBITDA excluding the gain or loss related to (i) restricted stock expense related to awards made to employees and the board of directors; (ii) disposal of assets and (iii) ICFA revenue. Adjusted net income and adjusted diluted earnings per common share reflect net income and diluted earnings per common share excluding (i) ICFA revenue; (ii) amortization related to ICFA intangible assets; (iii) disposal of assets and (iv) the tax effect of these items, as applicable.

Management believes that EBITDA, adjusted EBITDA, adjusted net income, and adjusted diluted earnings per common share are useful supplemental measures of our operating performance and provide our investors meaningful measures of overall corporate performance. EBITDA is also presented because management believes that it is frequently used by investment analysts, investors, and other interested parties as a measure of financial performance. Adjusted EBITDA, adjusted net income, and adjusted diluted earnings per common share are also presented because management believes that they provide our investors additional measures of our recurring core business. However, non-GAAP measures do not have a standardized meaning prescribed by GAAP, and investors are cautioned that non-GAAP measures, such as EBITDA, adjusted EBITDA, adjusted net income, and adjusted diluted earnings per common share, should not be construed as an alternative to net income, diluted earnings per common share, or other income statement data (which are determined in accordance with GAAP) as an indicator of our performance or as a measure of liquidity and cash flows. Management’s method of calculating EBITDA, adjusted EBITDA, adjusted net income, and adjusted diluted earnings per common share may differ materially from the method used by other companies and accordingly, may not be comparable to similarly titled measures used by other companies. A reconciliation of EBITDA, adjusted EBITDA and adjusted net income to net income and a reconciliation of adjusted diluted earnings per common share to diluted earnings per common share, the most comparable GAAP measures, are included in the schedules attached to this press release.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release and the related conference call include certain forward-looking statements which reflect the company’s expectations regarding future events. These forward-looking statements include, but are not limited to, statements about our strategies; expectations about future business plans, prospective performance, growth, and opportunities, including the potential for new service connections; future financial performance; regulatory and ACC proceedings, decisions and approvals, such as the outcome, timing and other statements regarding our plans, expectations and estimates relating to our rate cases and other applications with the ACC and other regulatory bodies, including with respect to the settlement agreement for the GW-Santa Cruz and GW-Palo Verde rate cases; our plans relating to future filings of our rate cases and other regulatory applications; acquisition plans and strategies, including our ability to complete additional acquisitions, and our expectations about future benefits of our acquisitions, such as projected revenue from our acquisitions, as well as our plans relating to the integration and upgrade of acquired water systems; statements concerning Arizona’s Assured Water Supply “Ag-to-Urban” program and ADOT’s SR 347 widening project, including anticipated benefits; population and growth projections; technologies, including expected benefits from implementing such technologies; revenue; metrics; operating expenses; trends relating to our industry, market, population and job growth, and housing permits; the adequacy of our water supply to service our current demand and growth for the foreseeable future; liquidity and capital resources; plans and expectations for capital expenditures; cash flows and uses of cash; dividends; depreciation and amortization; tax payments; our ability to repay indebtedness and invest in initiatives; the anticipated impact and resolutions of legal matters; the anticipated impact of new or proposed laws, including regulatory requirements, tax changes, and judicial decisions; the anticipated impact of accounting changes and other pronouncements; and other statements that are not historical facts, as well as statements identified by words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, or the negative of these terms, or other words of similar meaning. These statements are based on our current beliefs or expectations and are inherently subject to a number of risks, uncertainties, and assumptions, most of which are difficult to predict and many of which are beyond our control. Actual results may differ materially from these expectations due to changes in political, economic, business, market, regulatory, and other factors. Factors that may also affect future results are disclosed under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our filings with the Securities and Exchange Commission (the “SEC”), which are available at the SEC’s website at www.sec.gov. This includes, but is not limited to, our most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings with the SEC. Accordingly, investors are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s views as of the date hereof. We undertake no obligation to publicly update any forward-looking statement, except as required by law, whether as a result of new information, future developments or otherwise.

Company Contact:

Michael J. Liebman
CFO and SVP
Tel (480) 999-5104
[email protected]
Investor Relations:

Ron Both or Grant Stude
Encore Investor Relations
Tel (949) 432-7450
[email protected]

GLOBAL WATER RESOURCES, INC.

Condensed Consolidated Balance Sheets (unaudited)
     
(in thousands, except share and per share amounts) June 30, 2026 December 31, 2025
Assets    
Utility Plant $ 623,595   $ 610,766  
Less: accumulated depreciation   (177,826 )   (168,915 )
Net utility plant   445,769     441,851  
Current Assets    
Cash and cash equivalents   1,458     4,080  
Accounts receivable, net of allowance for credit losses of $235 and $244, respectively   3,746     3,746  
Unbilled revenue   4,128     3,409  
Prepaid expenses and other current assets   2,444     3,388  
Total current assets   11,776     14,623  
Other Assets    
Goodwill   6,512     6,512  
Intangible assets, net   5,938     6,062  
Regulatory assets   7,022     7,003  
Restricted cash   3,419     2,755  
Right-of-use assets, net   3,601     3,990  
Other noncurrent assets   117     117  
Total other assets   26,609     26,439  
Total Assets $ 484,154   $ 482,913  
Capitalization and Liabilities    
Capitalization    
Common stock, $0.01 par value, 60,000,000 shares authorized; 29,170,113 and 29,116,183 shares issued, respectively $ 286   $ 285  
Treasury stock, 374,761 and 359,329 shares, respectively   (2 )   (2 )
Additional paid-in capital   85,328     87,294  
Retained deficit   (768 )   (961 )
Total shareholders’ equity   84,844     86,616  
Long-term debt, net   127,828     129,756  
Total Capitalization   212,672     216,372  
Current Liabilities    
Accounts payable   1,042     2,251  
Customer and meter deposits   1,707     1,725  
Long-term debt, current portion   3,947     3,942  
Leases, current portion   638     850  
Accrued expenses and other current liabilities   9,892     10,457  
Total current liabilities   17,226     19,225  
Other Liabilities    
Revolver borrowings   5,800      
Long-term lease liabilities   3,528     3,741  
Deferred revenue – ICFA   21,919     22,772  
Regulatory liabilities   5,178     5,214  
Advances in aid of construction   155,659     155,414  
Contributions in aid of construction, net   39,931     37,857  
Deferred income tax liabilities, net   9,768     9,699  
Hook-up fee liabilities   8,218     8,410  
Other noncurrent liabilities   4,255     4,209  
Total other liabilities   254,256     247,316  
Total Capitalization and Liabilities $ 484,154   $ 482,913  
GLOBAL WATER RESOURCES, INC.

Condensed Consolidated Statements of Operations (unaudited)
     
  Three Months Ended

June 30,
Six Months Ended

June 30,
(in thousands, except share and per share amounts)   2026     2025     2026     2025  
Revenue        
Water service $ 8,404   $ 7,368   $ 15,010   $ 13,348  
Wastewater and recycled water service   7,252     6,873     13,932     13,350  
Unregulated revenue   2,111         2,111      
Total revenue   17,767     14,241     31,053     26,698  
Operating Expenses        
Operations and maintenance   4,556     3,917     8,739     7,604  
General and administrative   4,304     4,387     8,757     8,574  
Depreciation, amortization and accretion   4,401     3,317     8,662     6,645  
Total operating expenses   13,261     11,621     26,158     22,823  
Operating Income   4,506     2,620     4,895     3,875  
Other Income (Expense)        
Interest income   46     216     85     315  
Interest expense   (1,690 )   (1,496 )   (3,340 )   (2,974 )
Other, net   862     889     1,613     1,787  
Total other expense   (782 )   (391 )   (1,642 )   (872 )
Income Before Income Taxes   3,724     2,229     3,253     3,003  
Income tax expense   (977 )   (617 )   (872 )   (800 )
Net Income $ 2,747   $ 1,612   $ 2,381   $ 2,203  
         
Basic earnings per common share $ 0.10   $ 0.06   $ 0.08   $ 0.08  
Diluted earnings per common share $ 0.10   $ 0.06   $ 0.08   $ 0.08  
Dividends declared per common share $ 0.08   $ 0.08   $ 0.15   $ 0.15  
         
Weighted average number of common shares used in the determination of:        
Basic   28,781,145     27,463,169     28,769,816     25,925,155  
Diluted   28,809,269     27,504,578     28,804,360     25,986,878  
GLOBAL WATER RESOURCES, INC.

Condensed Consolidated Statements of Cash Flows (unaudited)
  Six Months Ended June 30,
(in thousands)   2026     2025  
Cash Flows from Operating Activities:    
Net income $ 2,381   $ 2,203  
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation, amortization and accretion   8,662     6,645  
Share-based compensation   412     280  
Deferred income tax expense   99     53  
AFUDC-Equity   (518 )   (556 )
Unregulated revenue   (2,111 )    
Operating lease expense   165     207  
Other adjustments   247     103  
Changes in assets and liabilities    
Accounts receivable and other current assets   173     (1,238 )
Accounts payable and other current liabilities   (704 )   (261 )
Other noncurrent assets   128     (77 )
Other noncurrent liabilities   221     1,468  
    Net cash provided by operating activities   9,155     8,827  
Cash Flows from Investing Activities:    
Capital expenditures   (12,915 )   (35,395 )
    Net cash used in investing activities   (12,915 )   (35,395 )
Cash Flows from Financing Activities:    
Dividends paid   (4,374 )   (3,928 )
Advances and contributions in aid of construction   2,909     3,007  
Refunds of advances for construction   (213 )    
Principal payments under finance lease   (230 )    
Repayments of long-term debt   (1,971 )   (1,965 )
Revolver borrowings   10,050      
Revolver repayments   (4,250 )    
Issuance of common stock, net of issuance costs       31,042  
Financing costs of debt and equity transactions       (259 )
Other financing activities   (119 )   (109 )
    Net cash provided by financing activities   1,802     27,788  
Increase (Decrease) in cash, cash equivalents, and restricted cash   (1,958 )   1,220  
Cash, cash equivalents, and restricted cash — Beginning of period   6,835     11,156  
Cash, cash equivalents, and restricted cash — End of period $ 4,877   $ 12,376  
Supplemental disclosure of cash flow information:
  Six Months Ended June 30,
(in thousands)   2026     2025
Cash and cash equivalents $ 1,458   $ 10,220
Restricted cash   3,419     2,156
Total cash, cash equivalents, and restricted cash $ 4,877   $ 12,376

A reconciliation of net income to EBITDA and adjusted EBITDA is as follows:

  Three Months Ended

June 30,
Six Months Ended

June 30,
(in thousands)   2026     2025     2026     2025  
Net Income $ 2,747   $ 1,612   $ 2,381   $ 2,203  
Income tax expense   977     617     872     800  
Interest income   (46 )   (216 )   (85 )   (315 )
Interest expense   1,690     1,496     3,340     2,974  
Depreciation, amortization and accretion   4,401     3,317     8,662     6,645  
EBITDA   9,769     6,826     15,170     12,307  
ICFA revenue1   (2,111 )       (2,111 )    
Loss on disposal of fixed assets2   131         131      
Restricted stock expense3   158     109     338     271  
EBITDA adjustments   (1,822 )   109     (1,642 )   271  
Adjusted EBITDA $ 7,947   $ 6,935   $ 13,528   $ 12,578  

A reconciliation of net income to adjusted net income and diluted earnings per common share to adjusted diluted earnings per common share is as follows:

  Three Months Ended

June 30,
Six Months Ended

June 30,
(in thousands, except share and per share amounts)   2026     2025   2026     2025
Net Income $ 2,747   $ 1,612 $ 2,381   $ 2,203
ICFA revenue1   (2,111 )     (2,111 )  
Loss on disposal of fixed assets2   131       131    
ICFA intangible amortization expense4         37    
Income tax effect of items above   499       490    
Adjusted Net Income $ 1,266   $ 1,612 $ 928   $ 2,203
         
Diluted weighted average common shares   28,809,269     27,504,578   28,804,360     25,986,878
         
Diluted earnings per common share $ 0.10   $ 0.06 $ 0.08   $ 0.08
Adjustments to diluted earnings per common share   (0.06 )     (0.05 )  
Adjusted diluted earnings per common share $ 0.04   $ 0.06 $ 0.03   $ 0.08
                     

1Represents unregulated revenue related to ICFA agreements previously recorded as deferred revenue.
2Represents the disposal of certain assets that were no longer used and useful following the completion of new water treatment assets.
3Represents noncash restricted stock expense for awards made to employees and the nonemployee directors.
4Represents amortization expense of intangible assets associated with ICFA payments received in the first quarter of 2026.



PLNT INVESTOR REMINDER: Planet Fitness, Inc. Investors Have Until September 14, 2026To Seek Lead Plaintiff Role

PLNT INVESTOR REMINDER: Planet Fitness, Inc. Investors Have Until September 14, 2026To Seek Lead Plaintiff Role

NEW YORK–(BUSINESS WIRE)–
If you have suffered a loss on your Planet Fitness, Inc. (“Planet Fitness” or the “Company”) (NYSE: PLNT) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

Investors have until September 14, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. Learn more about the lead plaintiff process and eligibility requirements here.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of November 6, 2025 and May 6, 2026, inclusive (“the Class Period”). The lawsuit alleges that Planet Fitness provided positive statements to investors that its “We Are All Strong on This Planet” marketing campaign was resonating and had “legs to extend into 2026,” expressed confidence in a planned national price increase for its Black Card premium membership to $29.99, and reaffirmed its fiscal year 2026 guidance and a new three-year growth plan while concealing material adverse facts concerning the true state of Planet Fitness’ customer acquisition. Specifically, the Company’s marketing had pivoted toward fitness-minded consumers and was alienating its core target demographic of fitness beginners and casual gym-goers. As a result, Planet Fitness was experiencing a significant headwind in net member joins during its peak first-quarter sign-up period that rendered its previously issued fiscal 2026 guidance and long-term financial targets unachievable.

On May 7, 2026, Planet Fitness announced financial results for the first quarter of 2026, revealing that its critical peak sign-up period was off to a slower-than-expected start internally. The Company cut full-year 2026 growth guidance, cutting same-store growth from 4-5% to 1%, and withdrew the long-term three-year growth algorithm it had introduced six months prior, attributing these results to marketing that failed to resonate with its core customer base, alongside external competition, macroeconomic, and weather-related impacts. The Company also announced it was pausing the planned national rollout of the Black Card price increase to prioritize revitalizing new membership growth. On this news, the price of Planet Fitness shares declined by $19.95 per share, or over 31%, from $63.96 per share on May 6, 2025 to close at $44.01 on May 7, 2026.

[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]

What Should I Do?

If you purchased or otherwise acquired Planet Fitness securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[WHAT IS A SECURITIES CLASS ACTION?]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kirby McInerney LLP

Lauren Molinaro, Esq.

212-699-1171

https://www.kmllp.com

https://securitiesleadplaintiff.com/

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

HUBG Investors With Significant Losses Must Act By August 28, 2026

HUBG Investors With Significant Losses Must Act By August 28, 2026

NEW YORK–(BUSINESS WIRE)–Kirby McInerney LLP reminds Hub Group, Inc. (“Hub Group” or the “Company”) (NASDAQ: HUBG) investors of the August 28, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Investors are encouraged to contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of April 28, 2023 through May 11, 2026, inclusive (“the Class Period”). The lawsuit alleges that the Company made materially false and misleading statements, including financial statements that were materially inaccurate due to premature revenue recognition, and the understatement of purchased transportation costs and accounts payable, as well as statements concerning the effectiveness of internal controls, and the Company’s drivers of financial results and growth.

On February 5, 2026, Hub Group announced that the Company’s financial statements for the first three quarters of 2025 should not be relied upon and would be restated due to “an error that resulted in the understatement of purchased transportation costs and accounts payable in the first nine months of 2025.” The Company revealed that its reports for those quarters “were in each case materially misstated due to the aforementioned error and should no longer be relied upon” and that “the Company [wa]s also continuing to assess the effectiveness of its disclosure controls and procedures and internal control over financial reporting and appropriate remediation steps.” The Company also estimated that “[t]he total amount of the reduction to accounts payable and purchased transportation costs related to this issue that was recorded during these periods is $77 million.” On this news, the price of Hub Group shares declined by $9.37 per share, or approximately 18%, from $51.33 per share on February 5, 2026 to close at $41.96 on February 26, 2026.

On May 12, 2026, Hub Group announced that it had “identified certain transactions that were prematurely or incorrectly recognized or not adequately supported,” causing its 2023 and 2024 annual reports filed with the SEC to be “materially misstated,” such that they “should no longer be relied upon.” The Company did not quantify the expected misstatement, although it “expect[ed] to conclude that it did not maintain effective disclosure controls and procedures and internal control over financial reporting for each of the years ended December 31, 2024 and 2023.” On this news, the price of Hub Group shares declined by $5.24 per share, or approximately 13%, from $41.86 per share on May 11, 2026 to close at $36.62 on May 12, 2026.

[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]

What Should I Do?

If you purchased or otherwise acquired Hub Group securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

What is the Lead Plaintiff Deadline?

Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. Learn more about the lead plaintiff process and eligibility requirements here.

[WHAT IS A SECURITIES CLASS ACTION?]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kirby McInerney LLP

Lauren Molinaro, Esq.

212-699-1171

https://www.kmllp.com

https://securitiesleadplaintiff.com/

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

Faraday Future Holds Special Meeting of Stockholders, Securing Approvals on a Number of Proposals to Support Continued EAI Robotics Development and Deliveries in 2026

Faraday Future Holds Special Meeting of Stockholders, Securing Approvals on a Number of Proposals to Support Continued EAI Robotics Development and Deliveries in 2026

  • Approval of the Private Placement Proposal will help the Company further its EAI Robotics goals in 2026, meet its contractual obligations, support future capital raising efforts, and enable mutual reinforcement between its core EAI business and the digital asset ecosystem.

  • The Company is scheduled to report its second quarter 2026 financial results after market close on Thursday, August 13, 2026, and will hold an earnings call at 4:00 p.m. where additional business updates will be communicated.

LOS ANGELES–(BUSINESS WIRE)–
Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future,” “FF,” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today announced the results of its Special Meeting of Stockholders held on August 12, 2026.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812299733/en/

Faraday Future Holds Special Meeting of Stockholders, Securing Approvals on a Number of Proposals to Support Continued EAI Robotics Development and Deliveries in 2026

Faraday Future Holds Special Meeting of Stockholders, Securing Approvals on a Number of Proposals to Support Continued EAI Robotics Development and Deliveries in 2026

At the Special Meeting, stockholders approved the Private Placement Proposal – in accordance with Nasdaq Listing Rule 5635(d), the issuance of Common Stock to holders of certain convertible notes. The Private Placement Proposal relates to the Company’s previously announced $25 million May 2026 financing. That financing formed part of the approx. $70 million in aggregate financing secured by the Company over the prior two months, which was intended to support Phase 1 of FF’s EAI robotics strategy. The financing also demonstrates institutional investors’ confidence in the Company’s business prospects moving forward.

FF continues to make strides on the product front, having completed the full-form EAI robot matrix across six series and three key form factors: humanoid, quadruped, and mobile manipulation. This executes FF’s “One Brain, Multiple Forms” vision, allowing a unified AI Brain to power diverse use cases—from industrial applications and security inspection to hospitality, entertainment, and education—via customized bodies, Agents, and Skills.

On the commercial front, the Company has progressed from product launches to active revenue generation, delivery, and scenario validation across hotels, catering, short-term rentals, and auto dealerships

FF’s EAI Robotics business continues to make strong momentum, achieving sales and shipments of 152 units for the month of July, setting another monthly record and securing a strong first-month win for the Q3 Robotics Practical Deployment Campaign under FF’s “Four-Core Full-Stack AI” ecosystem strategy. As of the end of July, cumulative sales and shipments reached 394 units for the year, as FF continued making steady progress toward its full-year shipment target of 2,000 units.

FF’s four industry ecosystems and productivity solutions—across education, industrial applications, security and inspection, and other existing markets—are rapidly taking shape, building sustained momentum for the continued ramp-up of sales and deliveries.

ABOUT FARADAY FUTURE

Founded in 2014, Faraday Future (FF) is a U.S.-based Physical AI ecosystem company dedicated to reshaping the future of robotics and mobility solutions through AI innovation and technologies. FF focuses on two major product strategies within the Embodied AI (EAI) robotics business: EAI humanoid and bionic robots, and EAI automotive-focused robots. By building a Three-in-One ecosystem of “Device, Data, EAI Brain & Open-Source and Open Platform,” FF aims to create an evolutionary flywheel: scaled device delivery, data collection and training, continuous evolution of the EAI Brain, stronger product capability, and even larger-scale delivery and deployment. Through this flywheel, FF seeks to maximize its commercial value and lead to the advancement of Physical AI. For more information, please visit Faraday Future’s official website: https://www.ff.com/

FORWARD LOOKING STATEMENTS

This press release includes “forward looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “plan to,” “can,” “will,” “should,” “future,” “potential,” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding FF’s entry into the embodied AI robotics market and robotics deliveries and development, potential financings and negotiations with existing convertible noteholders, involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.

Important factors, that may affect actual results or outcomes include, among others: the Company’s ability to continue as a going concern and improve its liquidity and financial position; the Company’s ability to pay its outstanding obligations, which it currently lacks; the availability of sufficient share capital to meet its current obligations and execute on its strategy; the willingness of convertible noteholders to fund the Company; demand for the Company’s robotics products; the ability of B2B preorder companies to locate customers to purchase our robotics products, on which their nonbinding preorders substantially depend; competition in the robotics industry, which includes companies with far superior experience, funding and name recognition; the ability of the Company to build an EAI education ecosystem that serves both the B2C consumer market and the B2B institutional education market; the acceptance by teachers and students of the Company’s robotics products in the education market; the ability of the Company to expand into additional markets for its robotics products; the Company’s reliance on a single OEM for most of its robotics products; the Company’s reliance on Chinese OEMs for all of its robotics products; the possibility of the federal government banning imports of Chinese robotics products; the Company’s ability to get the planned robotics products to comply with all applicable U.S. rules and regulations; the ability of the robotics OEM to timely supply robotics to the Company; tariff uncertainty for imported products, particularly from China; demand from automobile dealers for robotics products; the Company’s ability to homologate FX vehicles for sale; the Company’s ability to secure the necessary funding to execute on the FX strategy, which is substantial; the Company’s ability to secure an occupancy certificate covering all of its Hanford facility; the Company’s ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company’s limited operating history and the significant barriers to growth it faces; the Company’s history of substantial losses and expectation of continued losses; the success of the Company’s payroll expense reduction plan; the Company’s ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company’s estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company’s vehicles; the Company’s ability to cover future warranty claims; the success of other competing manufacturers; the performance and security of the Company’s vehicles; current and potential litigation involving the Company; the Company’s ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company’s indebtedness; the Company’s ability to use its “at-the-market” program; insurance coverage; general economic and market conditions impacting demand for the Company’s products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company’s control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company’s operations in China; the success of the Company’s remedial measures taken in response to the Special Committee findings; the Company’s dependence on its suppliers and contract manufacturer; the Company’s ability to develop and protect its technologies; the Company’s ability to protect against cybersecurity risks; and the ability of the Company to attract and retain employees, any adverse developments in existing legal proceedings or the initiation of new legal proceedings, and volatility of the Company’s stock price. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 14, 2026, and Form 10-K filed with the SEC on March 31, 2026, and other documents filed by the Company from time to time with the SEC.

Investors (English): [email protected]

Investors (Chinese): [email protected]

Media: [email protected]

 

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Technology General Automotive Robotics Automotive Manufacturing Manufacturing Finance Alternative Vehicles/Fuels Automotive Vehicle Technology Professional Services Artificial Intelligence Software Hardware Data Management

MEDIA:

Photo
Photo
Faraday Future Holds Special Meeting of Stockholders, Securing Approvals on a Number of Proposals to Support Continued EAI Robotics Development and Deliveries in 2026
Logo
Logo

INVESTOR ALERT: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit

PR Newswire

SAN DIEGO, Aug. 12, 2026 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”), have until September 28, 2026 to seek appointment as lead plaintiff of the Capicor class action lawsuit.  Captioned Nkamga v. Capricor Therapeutics, Inc., No. 26-cv-04385 (S.D. Cal.), the Capricor class action lawsuit charges Capricor as well as certain of Capricor’s top executives with violations of the Securities Exchange Act of 1934.

Robbins Geller Rudman & Dowd LLP

If you suffered substantial losses and wish to serve as lead plaintiff of the

Capricor

class action lawsuit, please provide your information here:


https://www.rgrdlaw.com/cases-capricor-therapeutics-class-action-lawsuit-capr.html
 

You can also contact attorneys

Ken Dolitsky

or

Michael Albert
 of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].

CASE ALLEGATIONS: Capricor is a biotechnology company focused on the development of cell and exosome-based therapeutics for the treatment of Duchenne muscular dystrophy, a rare genetic disorder characterized by progressive muscle degeneration and premature death. Its lead product candidate is Deramiocel, a cell therapy to address cardiac and skeletal muscle complications associated with Duchenne muscular dystrophy.

The Capricor class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Capricor adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for Deramiocel; (ii) the FDA had not agreed to those changes before Capricor resubmitted the Deramiocel Biologics License Application (“BLA”); (iii) as a result, there was a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness of Deramiocel; and (iv) as a result of the foregoing, there was a substantial risk to regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy.

On July 27, 2026, before the market opened, the FDA allegedly released briefing documents ahead of its July 29 advisory committee meeting for the BLA.  According to the complaint, the briefing documents explained that Capricor made changes to the pre-specified statistical analysis plan (“SAP”) and that the final version “was not submitted to FDA for review prior to BLA submission and was not discussed and consequently not agreed upon.”  The final version of the statistical analysis plan was allegedly created one day before the data was unblinded, and the FDA commented that the “FDA does not consider the conversion of raw change to percent change and then back to raw change to have been scientifically justified, as it adds complexity and reduces accuracy.”  The FDA allegedly further stated that it “considers [Capricor’s] analyses based on the post-study SAP versions to be post-hoc and exploratory.”  The complaint further alleges that the briefing documents concluded “the benefit-risk assessment for [D]eramiocel appears unfavorable in the absence of evidence of effectiveness.”

That same day, Capricor allegedly provided “an update,” stating that “‘Capricor has engaged fully and transparently with the FDA throughout the review process'” and that “‘[i]t is critical to understand that the post-hoc analyses in the FDA’s briefing materials rely on SAP version 1.1, an unsigned incomplete internal draft which became obsolete with the addition of cohort B and did not include content specifically requested by the FDA.'”  The Capricor class action lawsuit further alleges that Cantor Fitzgerald published an investor note that same day, stating the FDA’s “briefing documents paint an ugly picture” and “raise several concerns and make allegations about the integrity of data collecting.”  On this news, the price of Capricor stock fell 64%, according to the complaint.

On July 29, 2026, the advisory committee allegedly met to discuss the Deramiocel BLA.  The next day, Medscape reported that the panel relied on SAP version 1.1 as the “prespecified plan” and, in a non-binding 9-3 vote, the panel “concluded that the available evidence does not support the efficacy of deramiocel for treating DMD-associated cardiomyopathy.”  On this news, the price of Capricor stock fell 36%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Capricor securities during the Class Period to seek appointment as lead plaintiff in the Capricor class action lawsuit.  A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  A lead plaintiff acts on behalf of all other class members in directing the Capricor class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the Capricor class action lawsuit.  An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Capricor class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation.  Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025.  This marks our fourth #1 ranking in the past five years.  And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm.  With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.  Please visit the following page for more information:


https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices. 

Contact:
          Robbins Geller Rudman & Dowd LLP
          Ken Dolitsky
          Michael Albert
          655 W. Broadway, Suite 1900, San Diego, CA 92101
          800/851-7783
          [email protected] 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-capricor-therapeutics-inc-nasdaq-capr-investors-with-substantial-losses-have-opportunity-to-lead-shareholder-class-action-lawsuit-302850049.html

SOURCE Robbins Geller Rudman & Dowd LLP

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the REZILIENT3 trial, a global Phase 3 clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the first-line treatment of adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations, met its primary endpoint of progression-free survival (PFS) at a planned interim analysis.

In this analysis, the study demonstrated a statistically significant and clinically meaningful improvement in PFS in the zipalertinib containing arm. Observed safety for the zipalertinib containing arm was manageable. Based on these data, the Independent Data Monitoring Committee recommended unblinding the study. The trial will continue to monitor efficacy and safety.

Full results from REZILIENT3 will be submitted for presentation at an upcoming international medical conference. Based on these results, pending discussions with the U.S. Food and Drug Administration (FDA), Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics plan to pursue U.S. regulatory approval for this combination regimen in the first-line setting.

“The positive topline results from the planned interim analysis of REZILIENT3 further support the potential of zipalertinib to meet the high unmet medical need in patients with NSCLC harboring EGFR exon 20 insertion mutations,” said Harold Keer, MD, PhD, Chief Medical Officer, Taiho Oncology. “We look forward to pursuing regulatory approval of zipalertinib in combination with chemotherapy in the first-line treatment setting with the goal of providing a new treatment option for this group of patients.”

“Zipalertinib is a compound created through Taiho Pharmaceutical’s proprietary drug discovery technology,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “Achieving positive results in this Phase 3 trial in the first-line setting represents an important milestone for this program. We will continue to work closely with Taiho Oncology and Cullinan Therapeutics to bring zipalertinib in combination with chemotherapy to patients as soon as possible.”

“Meeting the primary endpoint early at a planned interim analysis marks an important milestone for the REZILIENT3 study and supports the potential role of zipalertinib in the first-line treatment setting,” said Jeffrey Jones, MD, MBA, Chief Medical Officer, Cullinan Therapeutics. “These topline results give us confidence in the potential for zipalertinib to offer a first-line treatment option for patients with NSCLC with EGFR exon 20 insertion mutations.”

About the REZILIENT3 Trial

This multicenter, randomized, controlled, open-label global trial enrolled 285 adults with previously untreated, locally advanced or metastatic non-squamous NSCLC with EGFR exon 20 insertion mutations. The primary objective of this trial is to assess progression-free survival in the zipalertinib plus chemotherapy arm versus the chemotherapy arm.

About Zipalertinib

Zipalertinib (development code: CLN-081/TAS6417) is an orally available small molecule designed to target activating mutations in EGFR. The molecule was selected because of its ability to inhibit EGFR variants with exon 20 insertion mutations. Zipalertinib is designed as a next generation, irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with non-small cell lung cancer. Zipalertinib is investigational and has not been approved by any health authority.

Zipalertinib is being developed by Taiho Oncology, Inc., its parent company, Taiho Pharmaceutical Co., Ltd., and in collaboration with Cullinan Therapeutics, Inc. in the U.S.

About EGFR Exon 20 Insertion Mutations

NSCLC is a common form of lung cancer and up to 4% of all cases globally have EGFR ex20ins.1 In the United States, approximately 16% of patients with NSCLC harbor EGFR mutations,1 with insertions at exon 20 accounting for up to 12% of these mutations.2

About Taiho Oncology, Inc.

The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development and commercialization of orally administered anti-cancer agents for various tumor types. Taiho Oncology has a robust pipeline of small-molecule clinical candidates targeting solid-tumor and hematological malignancies, with additional candidates in pre-clinical development. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Baar, Switzerland and Oakville, Ontario, Canada.

For more information, visit https://www.taihooncology.com/, and follow us on LinkedIn and X.

Taiho Oncology and the Taiho Oncology logo are registered trademarks of Taiho Pharmaceutical Co., Ltd.

About Taiho Pharmaceutical Co., Ltd. (Japan)

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (https://www.otsuka.com/en/), is an R&D-driven specialty pharma focusing on the fields of oncology and immune-related diseases. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology, in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts. In areas other than oncology, as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people’s quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people’s efforts to lead fulfilling and rewarding lives. For more information about Taiho Pharmaceutical, please visit https://www.taiho.co.jp/en.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding the company’s beliefs and expectations regarding the clinical development of zipalertinib, the safety and efficacy profile of zipalertinib and its potential to address unmet medical need, anticipated data results and our plans regarding future data presentations and other statements that are not historical facts. The words “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “potential,” “project,” “pursue,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of clinical trial data and regulatory submissions; the risk that any NDAs, INDs or other global regulatory submissions we may file with the United States Food and Drug Administration or other global regulatory agencies are not accepted or cleared on our expected timelines, or at all; the success of our clinical trials and preclinical studies; the risks related to our ability to protect and maintain our intellectual property position; the risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical trials will not be predictive of future results in connection with future studies or clinical trials; the effect of changes in global economic conditions, including uncertainties related to international trade policies, tariffs and supply chain dynamics on our business and operations; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither the company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made.

References

  1. Burnett H, Emich H, Carroll C, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. PLOS ONE. 2021;16(3): e0247620. Available at: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0247620.

  2. Riess JW, Gandara DR, Frampton GM, et al. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. Journal of Thoracic Oncology. 2018 Jul 5;13(10):1560–1568. Available at: https://www.jto.org/article/S1556-0864(18)30770-6/pdf.

 

Taiho Oncology

Leigh Labrie

+1 609.664.9878

[email protected]

Taiho Pharmaceutical Co., Ltd.

Junko Onishi

+81-80-1009-7683

[email protected]

Cullinan Therapeutics

Investors

Nick Smith

+1 401.241.3516

[email protected]

Media

Rose Weldon

+1 215.801.7644

[email protected]

KEYWORDS: Massachusetts New Jersey United States Japan North America Asia Pacific

INDUSTRY KEYWORDS: Oncology Health Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

Suzano Reports Adjusted EBITDA of R$4.7 Billion in the Second Quarter of 2026

Suzano Reports Adjusted EBITDA of R$4.7 Billion in the Second Quarter of 2026

SAO PAULO–(BUSINESS WIRE)–Suzano, the world’s largest pulp producer, announces its results for the second quarter of 2026 (2Q26), reporting higher prices, stronger volumes and improvements in Adjusted EBITDA and operating cash generation compared to the previous quarter. The quarterly results reflect the competitiveness and resilience of Suzano’s operations in a quarter marked by foreign exchange headwinds and pressure on input costs driven by higher oil prices affecting the industry as a whole.

Suzano sold 3.3 million tonnes of pulp and paper combined in 2Q26, comprising 2.9 million tonnes of pulp and 406 thousand tonnes of paper across the packaging, printing and writing, specialty and tissue segments. Net revenue totalled R$11.6 billion and adjusted EBITDA reached R$4.7 billion, both above the levels recorded in the previous quarter. Operating cash generation reached R$2.9 billion, while net income totalled R$1.8 billion in 2Q26.

Despite ongoing cost pressures, the cash cost of pulp production (excluding downtime) remained broadly stable year-on-year at R$843 per tonne. Suzano also maintains hedging policies to mitigate Brent price volatility.

Suzano’s leverage, measured by the ratio of net debt to adjusted EBITDA, ended the quarter at 3.4 times in USD. The company remains focused on deleveraging, supported by cash generation from its operations, efficiency improvement and capital allocation discipline.

“We have delivered a solid second quarter in a volatile market environment. We remain focused on operational efficiency and deleveraging, which will strengthen our resilience and the company’s competitiveness. At the same time, we will focus on capturing value from the investments already made, creating sustainable value for our stakeholders,” said Beto Abreu, CEO of Suzano.

Following the end of the quarter, Suzano completed the acquisition of a 51% stake in Arbex, the global tissue company formed with Kimberly-Clark, with cash payment of US$1.3 billion. Arbex began operations on July 1, 2026 and is focused on manufacturing, marketing and distributing consumer and professional tissue products in over 70 countries. The company comprises 22 mills across 14 markets. Arbex’s results will be consolidated into Suzano’s financial statements from the third quarter of 2026 onwards.

Hawthorn Advisors

Jamie Plotnek

[email protected]

KEYWORDS: Brazil United States South America North America Latin America Europe

INDUSTRY KEYWORDS: Packaging Other Manufacturing Manufacturing

MEDIA:

Logo
Logo

GNS Deadline: GNS Investors with Losses in Excess of $100K Have Opportunity to Lead Genius Group Limited Securities Fraud Lawsuit Against Citadel Securities LLC and Virtu Americas LLC

PR Newswire

NEW YORK, Aug. 12, 2026 /PRNewswire/ —

Rosen Law Firm Logo

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers or sellers of securities of Genius Group Limited (NYSE American: GNS) between April 12, 2022 and May 30, 2025, inclusive (the “Class Period”), of the important August 28, 2026 lead plaintiff deadline.

So What: If you purchased or sold Genius securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Genius class action, go to https://rosenlegal.com/cases/genius-group-limited/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants engaged in a manipulative and illegal trading practice known as “spoofing,” which involves submitting and then cancelling buy or sell orders without any genuine intent to execute them. The purpose of these “baiting orders” was to mislead other market participants about the true level of supply and demand for Genius securities, or about the stock’s price volatility, thereby influencing the market price of Genius to benefit defendants’ own trading positions. The alleged manipulation also increased investors’ transaction costs by inflating the bid-ask spread for Genius stock. Defendants entered thousands of these baiting orders on U.S. stock exchanges to create the false impression that Genius’ stock price reflected genuine supply-and-demand and volatility dynamics, while simultaneously profiting by absorbing and reselling their customers’ order flow at prices favorable to defendants.

To join the Genius class action, go to https://rosenlegal.com/cases/genius-group-limited/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/gns-deadline-gns-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-genius-group-limited-securities-fraud-lawsuit-against-citadel-securities-llc-and-virtu-americas-llc-302850205.html

SOURCE THE ROSEN LAW FIRM, P. A.